Development of a Novel Mucosal Vaccine Vector Derived From Human Parainfluenza Virus Type 2 and Its Efficacy as a SARS‐CoV‐2 Vaccine by Intratracheal Administration Using Transgenic Mice Expressing Human Angiotensin‐Converting Enzyme 2
Genes to Cells · 2025
DOI: 10.1111/gtc.70058 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes to Cells, 2025. Verfasst von Akira Kawano und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Molecular Genetics, Mie University Graduate School of Medicine, Tsu, Mie, Japan. Hauptthemen laut MEDLINE: Angiotensin-Converting Enzyme 2, SARS-CoV-2, COVID-19, COVID-19 Vaccines. Die Arbeit nennt 56 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
We created a novel replication‐incompetent vector derived from the human parainfluenza virus type 2 (hPIV2). The vector lacks the hemagglutinin‐neuraminidase ( HN ) gene (hPIV2/∆HN) that is essential for virus attachment and release. We also generated the stable packaging cell line expressing hPIV2 HN protein derived from Vero cells (Vero‐HN). As SARS‐CoV‐2 vaccines, we created hPIV2/∆HN‐based SARS‐CoV‐2 vaccines expressing the receptor binding domain of the spike protein (S‐RBD) of SARS‐CoV‐2, and S‐RBD with trimer formation domain (S‐RBD‐FD) with or without antigen 85B (Ag85B) having strong Th1‐type cytokine inducing activity. Intratracheal administration of S‐RBD‐FD/hPIV2/∆HN and S‐RBD‐FD/Ag85B/hPIV2/∆HN induced the S‐RBD‐specific neutralizing antibodies in sera of transgenic mice expressing human angiotensin‐converting enzyme 2 (hACE2/TG), and also the sera neutralized the pseudo‐typed lentivirus expressing the SARS‐CoV‐2 S protein. In particular, in an S‐RBD‐FD/Ag85B/hPIV2/∆HN‐administered group, high levels of neutralizing antibodies were induced also in the bronchoalveolar lavage fluid (BALF) in the hACE2/TG mice. Further, hACE2/TG mice vaccinated with S‐RBD‐FD/hPIV2/∆HN or S‐RBD‐FD/Ag85B/hPIV2/∆HN did not exhibit weight loss and showed a high survival rate after authentic SARS‐CoV‐2 challenge. These results suggested that S‐RBD‐FD/Ag85B/hPIV2/∆HN is a vaccine candidate against SARS‐CoV‐2. Finally, hPIV2/∆HN or Ag85B/hPIV2/∆HN vector will be potentially applicable to vaccine development and/or human gene therapy for respiratory tract diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology and Molecular Genetics, Mie University Graduate School of Medicine, Tsu, Mie, Japan.
- Laboratory of Immunoregulation and Vaccine Research, Tsukuba Primate Research Center, National Institute of Biomedical Innovation, Health and Nutrition, Tsukuba, Ibaraki, Japan.
- Leprosy Research Center, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japan.
- Department of Forensic Medicine and Sciences, Mie University Graduate School of Medicine, Tsu, Mie, Japan.
- Department of Food and Nutrition, Tsu City College, Tsu, Mie, Japan.
- Research and Development Department, Japan BCG Laboratory, Tokyo, Japan.
ORCID-Profile: Mitsuo Kawano, Yasuhiro Yasutomi
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Kawano, A., Asaka, M. N., Kawano, M., Sekijima, H., Sakai-Sugino, K., Komada, H., Yamakawa, N., Horibata, S., Matsuo, K., O'Brien, M., Nosaka, T., & Yasutomi, Y. (2025). Development of a Novel Mucosal Vaccine Vector Derived From Human Parainfluenza Virus Type 2 and Its Efficacy as a SARS‐CoV‐2 Vaccine by Intratracheal Administration Using Transgenic Mice Expressing Human Angiotensin‐Converting Enzyme 2. Genes to Cells. https://doi.org/10.1111/gtc.70058
Vancouver
Kawano A, Asaka MN, Kawano M, Sekijima H, Sakai-Sugino K, Komada H, et al. Development of a Novel Mucosal Vaccine Vector Derived From Human Parainfluenza Virus Type 2 and Its Efficacy as a SARS‐CoV‐2 Vaccine by Intratracheal Administration Using Transgenic Mice Expressing Human Angiotensin‐Converting Enzyme 2. Genes to Cells. 2025. doi:10.1111/gtc.70058
BibTeX
@article{Kawano2025,
author = {Kawano, Akira and Asaka, Masamitsu N and Kawano, Mitsuo and Sekijima, Hidehisa and Sakai-Sugino, Kae and Komada, Hiroshi and Yamakawa, Natsuko and Horibata, Shigeo and Matsuo, Kazuhiro and O'Brien, Myles and Nosaka, Tetsuya and Yasutomi, Yasuhiro},
title = {Development of a Novel Mucosal Vaccine Vector Derived From Human Parainfluenza Virus Type 2 and Its Efficacy as a SARS‐CoV‐2 Vaccine by Intratracheal Administration Using Transgenic Mice Expressing Human Angiotensin‐Converting Enzyme 2},
journal = {Genes to Cells},
year = {2025},
doi = {10.1111/gtc.70058}
}
EUVIMED